Radiation Shield Technologies Offers Patented Demron Apparel Providing Healthcare Workers and First Responders Unique Anti-Coronavirus Protection

“The standard gear worn by healthcare workers and first responders is ineffective at preventing transmission of the Coronavirus,” said Ronald DeMeo, M.D., CEO of Radiation Shield Technologies, the surgeon who developed the technology.

Demron provides the highest protection that cannot be found anywhere else. With this deadly virus posing an increased risk to those caring for the afflicted as well as the general public, it is critical for healthcare workers and first responders to wear the latest gear offering the highest protection.”

Dr. DeMeo received global news attention in 2011 when he recognized that emergency responders in Japan lacked proper gear while working to contain the country’s worst nuclear crisis since 1945. His Miami-based company then donated Demron full-body nuclear radiation protection suits to protect power plant workers and rescue teams. Similarly, Dr. DeMeo is now issuing a call-to-action to help ensure American healthcare workers and first responders utilize the appropriate gear to minimize Coronavirus contamination risk.

In addition to face masks that provide the highest level of protection against disease transmission, the Demron suits have patented thermal conductive capabilities that enable health-care workers suits to be externally monitored for the onset of fever, one of the first signs of the disease.

Additionally, Coronavirus-infected patients can also be monitored and externally cooled when infection transportation chambers are lined with the Demron fabric. Ongoing testing in this area is being carried out by Dipl. Eng. Pavel Castulik, Ph.D., at the Research Centre for Toxic Compounds in the Environment, Masaryk University, Czech Republic.

Demron, manufactured solely by RST, is the world’s first and only CBRN fabric that provides chemical, biological, radiological, and nuclear protection, while also enabling external temperature monitoring.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  
Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.
The decision cancels each of the original claims of the '345 Patent and declares unpatentable each of Swift's proposed substitute claims. Amongst the prior art deemed by the USPTO to render the '345 Patent unpatentable is a patent application licensed to MolecuLight that lists MolecuLight's Founder, Dr. Ralph DaCosta, as the sole inventor.
It combines the convenience of the Kaleido insulin pump with two market-leading innovations designed by Diabeloop and Dexcom to create a Hybrid Closed Loop system for managing type 1 diabetes which is flexible, self-learning and easy to use.

By using this website you agree to accept Medical Device News Magazine Privacy Policy